Updates On Aflibercept BPCIA Litigation - Life Sciences, Biotechnology & Nanotechnology

On Friday, January 20, 2024, Regeneron Pharmaceuticals, Inc. ("Regeneron") filed an ex parte application for a scheduling order setting the schedule for preliminary injunction proceedings or, in the alternative, an emergency status conference.

Related Keywords

California ,United States ,Northern District ,West Virginia ,Samsung Bioepis ,Celltrion Inc ,Amgen ,Regeneron Pharmaceuticals Inc ,Amgen Inc ,Judicial Panel ,Us District Court ,Samsung Bioepis Co ,Judicial Panel On Multidistrict ,Mylan Pharmaceuticals Inc ,Biocon Biologics Inc ,Regeneron Pharmaceuticals ,Central District ,Chief Judge Kleeh ,Multidistrict Litigation ,Mylan Pharmaceuticals ,Big Molecule Watch ,Mondaq ,Aflibercept ,Celltrion ,Eylea ,Formycon ,Litigation ,Regeneron ,Egeneronv Amgen ,Egeneronv Celltrion ,Egeneronv Formycon ,Regeneronv Mylan ,Egeneronv Samsung Bioepis ,Amsung Bioe ,Food ,Drugs ,Healthcare ,Life Sciences ,Iotechnology Amp Nanotechnology ,Intellectual Property ,Patent , ,